Beginning in 2021, The Henri Termeer Transatlantic Connections Award, with the support of the Termeer Foundation and Health Holland, selects two young life science entrepreneurs, one in Massachusetts and one in the Netherlands. Awardees are currently leading innovative biomedical research activities, and their programs have the potential to strengthen transatlantic relations between the two life science regions. Candidates will be selected based on their initial entrepreneurial success in establishing a life science company that meets certain scientific and financial criteria, exhibit a strong interest in mentoring other young entrepreneurs, and a willingness for additional involvement in Termeer Foundation programs. Awardees also receive Fellowship status within The Termeer Foundation, which includes access to experienced healthcare mentors, networking with fellow peer entrepreneurs, and recognition at the 2021 Termeer Fellows Celebration. Recipients are invited to spend a week visiting their fellow awardee’s company, and to participate in additional learning, networking and cultural events in that location.

The 2021 Henri Termeer Transatlantic Connections Award honorees are: Eline van Beest, CEO, Hybridize Therapeutics; and Joshua Cohen and Justin Klee, co-Founders and co-CEOs of Amylyx Pharmaceuticals.

images/news/elinevanbeest_300.jpg

Eline van Beest

Hybridize Therapeutics

Eline van Beest
images/news/joshuacohen_300.jpg

Joshua Cohen

Amylyx Pharmaceuticals

Joshua Cohen
images/news/justinklee_300.jpg

Justin Klee

Amylyx Pharmaceuticals

Justin Klee

~  Eline van Beest is CEO of Hybridize Therapeutics, an early-stage Dutch biotechnology company focused on developing virus-specific RNA-based therapies. She has a technical background with a Masters degree in Industrial Design Engineering (Delft University of Technology, Cum Laude), and has further education in business innovation and coaching. She is CEO of Hybridize Therapeutics, an early-stage Dutch biotechnology company focused on developing virus-specific RNA-based therapies. She is also the founder and CEO of NightBalance, a leading innovator of obstructive sleep apnea (OSA) technology. While building the venture, Eline gained experience in medical product development, international clinical trials, getting reimbursement coding, filing and protecting Intellectual Property, commercializing a medical innovation, fundraising and building teams and medical advisory boards. NightBalance was acquired by Philips in May 2018.

Also, Eline holds a position as a member of the Supervisory Board of Livassured, a company that introduces a smart wearable that warns caretakers on epileptic seizures. Eline was nominated for several lists of female and/or tech entrepreneurs like amongst others the Rising Star at the World Women’s Forum and 35 Innovators Under 35 by MIT.

~ Justin Klee and Joshua Cohen co-founded Amylyx Pharmaceuticals in 2013. Today, they serve as co-CEOs and have overseen the development of an investigational product for ALS and Alzheimer’s disease by working with top hospitals and investigators around the country, raising over $100,000,000 in funding and overseeing all preclinical, regulatory and clinical operations and strategy to bring AMX0035 through clinical trials.

Josh and Justin have built a team of industry leaders, rapidly growing the company to over 30 full time employees in recent years. In 2020, the company announced the detailed CENTAUR trial results that were published in the New England Journal of Medicine (NEJM), which showed a significant slowing in ALS disease progression compared to placebo, providing hope for people with ALS.

Justin previously did research at Brown University in neural systems and neurophysiology and Alzheimer’s disease at Harvard Medical School and received his Sc.B in Neuroscience from Brown University, while Josh’s research experience includes work both at Brown University and at the National Institute of Standards in Technology. Josh received his BSE in biomedical engineering from Brown University. In 2019, Josh and Justin won Xconomy’s Young Innovator Award and in 2020 were named to Business Insider’s 30 under 40 in health care list and PM360’s Elite in the Drug Researchers and Developers Category. Amylyx was also selected as one of Fierce Biotech’s 2020 Fierce 15 companies.


 

termeer logo bottom